Vitamin D receptor genotypes are not associated with clinical response to calcipotriol in Korean psoriasis patients

Abstract

Conflicting results have been reported on the association between BsmI restriction fragment length polymorphism (RFLP) at the vitamin D receptor gene (VDR) locus and the clinical response of psoriasis patients to calcitriol or calcipotriol therapy. We evaluated RFLPs of the VDR gene by analyzing the restriction pattern of polymerase chain reaction products in 55 Korean psoriasis patients receiving topical calcipotriol therapy, and evaluated the clinical response. Of the 55 patients, 43 completed the 8-week treatment protocol, and the response was evaluated as excellent in 9 patients, good in 20, and poor in 14. Thus, in our 43 patients BsmI and ApaI polymorphism in the VDR gene did not correlate with response to calcipotriol. The marked predominance of the b allele in the Korean population precludes the possibility that BsmI polymorphism is associated with clinical response to calcipotriol. The pattern of prevalence of the VDR genotypes in the Korean population is very different from that in Western populations. There were no differences in VDR genotype between controls and psoriasis patients at the BsmI site, but there were significant difference in terms of ApaI RFLP as previously reported. In conclusion, polymorphism analysis of the VDR gene with BsmI and ApaI restriction enzymes in psoriasis patients was not helpful in predicting clinical response to calcipotriol.

Vitamin D receptor gene polymorphisms and haplotypes (Apa I, Bsm I, Fok I, Taq I) in Turkish psoriasis patients

“…Mee et al in 1998 [9] found the Aa genotype has been associated with early onset of psoriasis. Lee et al in 2002 [28] and Kontula et al in 1997 [29] reported there was no correlation between Bsm I and Apa I polymorphisms and clinical response.…”

Vitamin D receptor gene polymorphism is not associated with psoriasis in the Italian Caucasian population

“…In a Korean population, a significant difference in VDR genotypes between normal controls and psoriatic patients, especially those with early onset, was demonstrated [5]. However, no role for the polymorphism analysis of VDR in predicting clinical response to calcipotriol [6,9] was found, nor any correlation between VDR and psoriasis clinical variety [10]. Few studies deal with other ethnic groups, being limited to the report of the ''aa'' and ''Aa'' VDR genotypes as risk factor for the development of psoriasis vulgaris in the Turkish population [8].…”

“…In recent years, some studies [5][6][7][8][9][10] reported an association between psoriasis and VDR polymorphisms. In a Korean population, a significant difference in VDR genotypes between normal controls and psoriatic patients, especially those with early onset, was demonstrated [5].…”

Psoriasis and Other Skin Diseases

“…While no differences in VDR genotype between controls and psoriasis patients were reported at the BsmI site, some studies reported significant difference in terms of ApaI SNP [40] and FokI SNP [41]. Additionally, it has been shown that vitamin D receptor genotypes are not associated with clinical response to calcipotriol (a topical analog used in psoriasis) at least in Korean psoriasis patients [42]. Kontula et al [43] and Mee et al [44] studied the BsmI polymorphism and the response to calcipotriol treatment in psoriatic patients and found no association between them.…”